Gefapixant information

Gefapixant
Clinical data
Trade names	Lyfnua
Other names	MK-7264
ATC code	R05DB29 (WHO) ;
Legal status
Legal status	EU: Rx-only;
Identifiers
	IUPAC name 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide;
CAS Number	1015787-98-0;
PubChem CID	24764487;
DrugBank	DB15097;
ChemSpider	58828660;
UNII	6K6L7E3F1L;
KEGG	D11349;
ChEMBL	ChEMBL3716057;
CompTox Dashboard (EPA)	DTXSID401337212 ;
ECHA InfoCard	100.258.106
Chemical and physical data
Formula	C14H19N5O4S
Molar mass	353.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC;
	InChI InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19); Key:HLWURFKMDLAKOD-UHFFFAOYSA-N;

Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough.^[1] It acts as an antagonist of the P2RX3 receptor.^[2]^[3]^[4]

It was approved for medical use in the European Union in September 2023.^[1]

^ ^a ^b ^c "Lyfnua EPAR". European Medicines Agency. 29 September 2023. Retrieved 5 October 2023.
^ Muccino D, Green S (June 2019). "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics. 56: 75–78. doi:10.1016/j.pupt.2019.03.006. PMID 30880151. S2CID 81982653.
^ Richards D, Gever JR, Ford AP, Fountain SJ (July 2019). "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology. 176 (13): 2279–2291. doi:10.1111/bph.14677. PMC 6555852. PMID 30927255.
^ Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents. 29 (12): 943–963. doi:10.1080/13543776.2019.1693542. hdl:11581/435751. PMID 31726893. S2CID 208037373.

[Lyfnua_EPAR-1] "Lyfnua EPAR". European Medicines Agency. 29 September 2023. Retrieved 5 October 2023.

[pmid30880151-2] Muccino D, Green S (June 2019). "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics. 56: 75–78. doi:10.1016/j.pupt.2019.03.006. PMID 30880151. S2CID 81982653.

[pmid30927255-3] Richards D, Gever JR, Ford AP, Fountain SJ (July 2019). "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology. 176 (13): 2279–2291. doi:10.1111/bph.14677. PMC 6555852. PMID 30927255.

[pmid31726893-4] Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents. 29 (12): 943–963. doi:10.1080/13543776.2019.1693542. hdl:11581/435751. PMID 31726893. S2CID 208037373.

Gefapixant information

and 28 Related for: Gefapixant information

Gefapixant

Methotrexate

Purine

Cytosine

ATC code R05

Nucleotide

Phenolphthalein

Fenethylline

Allopurinol

Uric acid

Pentoxifylline

Caffeine

Inositol

Ticagrelor

Febuxostat

Guanine

Ivermectin

Nucleoside

Quercetin

Cytidine monophosphate

Phytic acid

Propolis

Apigenin

Theophylline

Uridine monophosphate

Phenol red

Xanthine

Ribose